iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
SVR Improves Steatosis in GT-3..... Associations of chronic hepatitis C with metabolic and cardiac outcomes
  Download the PDF here
Download the PDF here
Herein are 2 studies, the 2nd study reports the association between HCV & cardiac & metabolic disease (steatosis [fatty liver]diabetes, insulin resistance, hypertension). The 1st study immediately below reports that SVR in GT-3 reduced or eliminated steatosis......
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C......"In patients infected with genotype 3 HCV.....[for sustained responders].....the steatosis will disappear in half of them."
Hepatology 2003
Thierry Poynard,1 Vlad Ratziu,1 John McHutchison,2 Michael Manns,3 Zachary Goodman,4 Stefan Zeuzem,5 Zobair Younossi,6 and Janice Albrecht7
Abstract: It has been suggested that hepatitis C virus (HCV) and especially genotype 3 is associated with steatosis. We assess the effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis. We analyzed 1,428 naïve patients included in a randomized trial. A single pathologist scored steatosis at baseline and 24 weeks after the treatment. At baseline, steatosis was present in 935 of 1,428 patients (65%), including 175 (83%) of 210 patients with genotype 3 versus 760 (62%) of 1,218 with other genotypes (P < .001). The variables associated with steatosis in logistic regression were genotype 3 (P < .001), triglycerides greater than 1.7 mmol/L (P < .001), body mass index greater than 27 (P < .04), age greater than 40 years (P < .001), and septal fibrosis (P = .007). In genotype 3-infected patients, steatosis was associated with high viral load and with lower serum cholesterol. Steatosis was associated with lower sustained response rate, even after taking into account other factors (P < .001). Among virologic responders, steatosis was much improved in genotype 3, improvement of at least 1 grade in 77%, and disappearance in 46% compared with other genotypes, 46% and 29%, respectively (P < .001 both comparisons). In genotype 3 responders, the baseline low serum cholesterol was corrected by treatment (P < .001). Steatosis was associated with HCV genotype 3, triglycerides, high body mass index, age, fibrosis stage, and lower virologic response to treatment. In conclusion, sustained disappearance of the virus is associated with reduction of steatosis in genotype 3 as well as a correction of baseline low serum cholesterol.
After treatment, there was a significant increase of cholesterol levels among responders both in genotype 3 (0.84 mmol/L, P .0001) and in genotype non-3 responders (0.34 mmol/L, P .0001). There was no difference in non responders.
Associations of chronic hepatitis C with metabolic and cardiac outcomes Alimentary Pharmacology & Therapeutics
March 2013
Z. M. Younossi*,, M. Stepanova*, F. Nader*, Z. Younossi & E. Elsheikh* *Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA.
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.

Chronic hepatitis C virus (CH-C) infection is associated with metabolic conditions such as insulin resistance and type 2 diabetes (DM) and may increase the risk of cardiovascular diseases.
To assess the association of CH-C with risk factors for cardiovascular diseases using US population data.
The National Health and Nutrition Examination Surveys (NHANES) collected between 1999 and 2010 were used.
Of 19 741 participants considered eligible for the study, 173 individuals (0.88%) had detectable HCV RNA and were considered to have CH-C. Compared with controls, CH-C patients were predominantly African American (23.5% vs. 10.5%, P < 0.0001), men (66.6% vs. 46.1%, P = 0.0001), more likely to be between 45 and 55 years of age (41.9% vs. 20.4%, P = 0.0001), had higher rate of insulin resistance (44.1% vs. 31.1%, P = 0.0301), hypertension (40.1% vs. 28.9%, P = 0.0201), and history of smoking (76.2% vs. 29.9%, P < 0.0001). In multivariate analysis, in addition to known risk factors for insulin resistance, CH-C was independently associated with the presence of insulin resistance [OR (95% CI) = 2.06 (1.19-3.57)], DM [OR = 2.31 (1.18-4.54)] and hypertension [OR = 2.06 (1.30-3.24)]. Independent predictors of cardiovascular diseases included older age, presence of obesity and smoking. CH-C was independently associated with congestive heart failure subtype of cardiovascular diseases but not ischaemic heart disease and stroke.
Chronic hepatitis C virus infection is independently associated with presence of metabolic conditions (insulin resistance, type 2 diabetes mellitus and hypertension) and congestive heart failure.
Hepatitis C virus (HCV) is the most common cause of cirrhosis and hepatocellular carcinoma in the United States.[1, 2] In addition, HCV is associated with a number of important extrahepatic manifestations.[3] Of these, there is increasing evidence that HCV infection increases the risk for type 2 diabetes (DM) and insulin resistance (IR). In fact, previous data indicated that in individuals older than 39 years of age, HCV infection increases the risk of DM by almost 4 times.[4] In addition, in longitudinal studies, development of DM has been reported to be 11 times more common in those infected with HCV than those who were not.[5] Although the association of HCV with DM has been confirmed, its underlying mechanism remains unknown. Some of these mechanisms include direct interaction of HCV proteins with the hepatocyte insulin signalling cascade[6-8] or impairment of pancreatic ß-cell function.[9] In addition, recent evidence suggests involvement of the striated muscle in the pathogenesis of IR in patients with CH-C.[10]
The consequences of IR and DM in HCV-infected patients can be divided into those that affect liver disease outcomes and those affecting nonliver related outcomes.[11]HCV patients with DM or IR tend to have more advanced hepatic fibrosis, hepatocellular carcinoma and lower efficacy of treatment regimens.[12] In addition to metabolic conditions (DM and IR), HCV has also been associated with arthrosclerosis and coronary artery disease.[13-15] Although HCV and its contribution to DM and IR can explain some of these associations, the exact underlying mechanism of how CH-C can predispose to cardiovascular complications remains unknown. The aim of this study was to assess the independent association of HCV with metabolic conditions (DM, IR, hypertension and hyperlipdaemia) as well as cardiovascular complications using a large population-representative sample.
Study sample

Our study uses the data derived from the National Health and Nutrition Examination Survey (NHANES), a nationwide survey that represents the health and nutritional status of the of the non-institutionalised civilian US population. The data were collected by the US National Center for Health Statistics (NCHS) with the Centers for Disease Control and Prevention (CDC), and it is currently publicly available. Detailed description of NHANES study design and methods are available elsewhere.[16] For the purpose of the study, we used six cycles of continuous NHANES collected between 1999 and 2010. These surveys were based on similar questionnaires and similar methods for serum and blood assays.
The NHANES participants were included in the study if they were age of 18 years or older, had complete demographic and relevant clinical data including HCV serologic tests and completed questionnaires with history of cardiovascular diseases. Additional data used in the study included body mass index (BMI), waist circumference and blood pressure which were measured at the time of examination by the NHANES representatives for all eligible participants. The data from a number of questionnaires and laboratory tests were also used for our study, namely, alcohol consumption and smoking history, fasting serum glucose and insulin, HDL cholesterol, LDL cholesterol and total cholesterol, AST, ALT, transferrin saturation and serologic tests for HBV (hepatitis B surface antigen, or HBsAg) and HCV (anti-HCV by ELISA followed by HCV RNA by PCR for HCV positive or indeterminate samples). Participants with insufficient data for ruling in HCV infection or ruling out chronic liver disease were excluded from the study.
Study definitions
Definitions for metabolic conditions used in the study have been previously described.[17] Briefly, insulin resistance was defined as HOMA score greater than 3.0, type II diabetes was defined as fasting blood glucose of greater than 125 mg/dL or the use of hypoglycaemic agents, and hypertension was defined as blood pressure (average of four readings) of greater than 140/90 mmHg or the use of antihypertensive medications. Furthermore, obesity (BMI ≥ 30.0) and visceral obesity (waist circumference greater than 102 cm in men or 88 cm in women) were also evaluated for all eligible participants.
The history of cardiovascular disease was established using a medical conditions questionnaire where NHANES participants were asked about a number of chronic conditions and if they were ever diagnosed by a healthcare provider. For the purpose of the study, ischaemic heart disease (IHD) was defined as self-reported history of coronary artery disease or heart attack. Furthermore, the history of stroke and congestive heart failure was also collected for eligible participants, and these two conditions together with IHD, as defined above, were used to establish the diagnosis of cardiovascular diseases (CVD). Smoking was defined as ongoing smoking (a question SMQ040 'Do you now smoke cigarettes?' answered either 'Every day' or 'Some days') and given a total number of cigarettes smoked in life exceeds one hundred. The data were collected from the Smoking and Tobacco Use questionnaire during NHANES data collection.
Chronic HCV infection
All sera from NHANES participants were tested for antibody to hepatitis C virus (anti-HCV). Sera testing positive for anti-HCV were tested further for HCV RNA. Participants with positive HCV RNA were considered to have chronic hepatitis C (CH-C). On the other hand, individuals without any evidence of chronic liver disease such as excessive alcohol consumption (defined as self-reported consumption of >20 g/day for at least a year for men, and >10 g/day for women), elevated aminotransferases (ALT > 40 U/L or AST > 37 U/L for men, AST and ALT > 31 U/L for women), elevated transferrin saturation (>50%), HBV infection (positive HBsAg) were presumed not to have chronic liver disease and were further used as controls. Patients with presumed non-alcoholic fatty liver disease (elevated liver enzymes with no evidence of other liver diseases or excessive alcohol consumption), were also excluded. Participants with data insufficient to rule-in HCV infection or rule-out CLD were excluded from the study.
Statistical analysis
The prevalence of various clinical parameters, including CVD, its subtypes and metabolic conditions, was compared between those with and without HCV infection using the stratum-specific chi-squared test for independence. Furthermore, logistic regression was used to identify independent predictors of CVD and its risk factor while adjusting for potential clinical and demographic confounders. P value <0.05 was selected to identify potentially statistically significant associations.
For the purpose of the study, all sampling errors were calculated by Taylor linearisation. Sampling weights calculated for each NHANES participant were used to account for nonresponse and unequal selection probabilities, so, after weighing, the study cohort is designed to be representative of the US population. Furthermore, stratification and sampling units that describe the design stages of the NHANES data collection were used to account for the complex, multi-stage probability sample design of these data. According to the NHANES Analytic and Reporting Guidelines,[16] when merging several analytic cycles, adjustment coefficients were applied to all sampling weights. All analyses were run using standalone sudaan 10.0 (SAS Institute Inc., Cary, NC, USA). The study was granted an exemption from full review by Inova Institutional Review Board (VA, USA).
From NHANES 1999-2010, 19 741 individuals were considered eligible for the study. Of the study cohort, 173 (0.88%) individuals tested positive for HCV RNA and were presumed to have CH-C, and 19 568 had no evidence of chronic liver disease and, therefore, were used as controls.
The results of pairwise comparison of the CH-C cohort to controls without liver disease are summarised in Table 1. Expectedly, individuals with hepatitis C were less likely to be Caucasian (62.0% vs. 72.5%, P = 0.0202) and more likely to be African American (23.5% vs. 10.5%, P < 0.0001), predominantly men (66.6% vs. 46.1%, P = 0.0001), more likely to be between 45 and 55 years of age (41.9% vs. 20.4%, P = 0.0001) and less likely to be older than 65 (3.70% vs. 14.5%, P < 0.0001). Of the metabolic conditions known to be associated with increased cardiac risks, insulin resistance and hypertension were observed significantly more frequently in those with CH-C (44.1% vs. 31.1%, P = 0.0301 and 40.1% vs. 28.9%, P = 0.0201 respectively) (Table 1). The rate of smoking in the CH-C cohort was also significantly higher (76.2% vs. 29.8%, P < 0.0001).
Older age is known to be a major contributor to the risk of cardiovascular disease. At the same time, the CH-C cohort was found to be significantly younger than average for the population: only 3.70% of those actively infected with HCV were 65 years old or older, compared to 14.46% in controls (P < 0.0001). To better separate the impact of age to the risk of CVD from that of CH-C, we evaluated the association of CH-C and CVD in different age groups separately (Table 2). A significantly higher rate of congestive heart failure (CHF) in HCV-infected individuals was found for those of 64 years of age or younger: 3.84 ± 1.50% vs. 0.89 ± 0.08% in controls of the same age, P = 0.0467. Other cardiovascular diseases were not different between those with and without HCV in all studied age groups (data not shown). Furthermore, since the rate of smoking, was found to be significantly higher in those with CH-C, we also studied smoking and nonsmoking CH-C cohorts separately. In these two separate rounds of analysis, no association of CH-C with CVD or its subtypes was found as well (all P > 0.05, data not shown).
Independent predictors of metabolic conditions and cardiovascular diseases In multivariate analysis, after adjustment for other major contributors metabolic conditions such as older age, obesity and non-Caucasian race or ethnicity, CH-C was found to be independently associated with type II diabetes [OR (95% CI) = 2.90 (1.35-6.19)], hypertension [OR = 2.01 (1.18-3.41)] and insulin resistance [OR = 2.20 (1.16-4.17)] (Table 3), and similar associations were observed when smoking and nonsmoking cohorts were studied separately (data not shown).
In multivariate analysis, CH-C was also independently associated with congestive heart failure [OR (95% CI) = 2.49 (1.04-5.96)] after controlling for age, obesity and smoking. No other independent association between CH-C and overall CVD diagnosis or other subtypes of CVD (IHD and Stroke) could be established (Table 4).
This study assesses the association of CH-C with metabolic conditions and cardiovascular diseases using a general population database. Our study shows that CH-C is independently associated with three important metabolic conditions: IR, DM and hypertension. Although the association of HCV with IR and DM has been previously reported,[18-24] the association of HCV with hypertension is a novel finding.[3, 4] In fact, in one of our previous population-based studies,[21] we reported that the association of HCV with IR and DM might have been attenuated in the last decade by the epidemics of obesity. In this study, having a larger sample from additional NHANES cycles, we confirm that the association between HCV and IR/DM, in fact, remains significant and strong at the population level.
These associations have been shown to be related both to the host factors as well as viral factors. In fact, HCV has been shown to affect glucose-insulin homeostasis as well as lipid metabolism and lipid synthesis.[7-12, 18] In addition, viral factors such as HCV genotypes and HCV core protein can have a direct impact on these interactions.[12] These are significant evidence to support the notion that HCV predisposes patients to insulin resistance and possibly other metabolic abnormalities with their potential consequences such as cardiovascular diseases.[22]
In addition to an increased risk for metabolic conditions, our data show that CH-C is also independently associated with an important subtype of cardiovascular disease, congestive heart failure. This association was present after controlling for important confounders associated with both metabolic conditions as well as cardiovascular diseases, namely, age, smoking and obesity. Although previous studies have suggested an increased risk of carotid atherosclerosis in patients with CH-C,[22-25] the most important association between HCV and coronary artery disease (CAD) has been reported in the HIV/HCV co-infected cohort.[26] In fact, another study reported that the risk of acute myocardial infarction in patients with CH-C was not increased.[27] However, other recent studies have suggested evidence for myocardial injury and left ventricular systolic and diastolic dysfunction in patients with CH-C.[28-30] Our findings may have important clinical and public health implications. It is estimated that about 4 million people are infected with CH-C in the United States and over 130 million people are infected worldwide. The vast majority of CH-C patients have not yet been diagnosed and remain untreated. In the United States, the highest prevalence of HCV infection is in the so called 'Baby Boomers'.[31] As this group gets older, the burden of HCV-related complications is expected to increase tremendously.[1] In addition, we believe that the metabolic and cardiovascular complications of HCV can add to this tremendous clinical and economic burden, potentially making CH-C one of the most important chronic diseases for the next few decades.
The main weakness of our study is the lack of follow-up for the target cohort. Since the majority of HCV-infected individuals are still younger than 65 years and therefore are relatively healthy, we may not be able to explicitly appreciate the association of metabolic and cardiovascular conditions with HCV given the low overall rate of these conditions in the predominantly middle-aged CH-C population. However, we believe that with ageing of the target CH-C population, it may become possible to highlight the impact of HCV infection to the natural history of CVD with higher significance and impact. Furthermore, we used self-reports which may have led to underestimation of the true rate of CVD in patients with CH-C and controls. However, the systematic data collection for both CH-C and the controls was the same which should minimise any real bias towards one group. Also, the study is based on a large sample representative of the non-institutionalised US population which contains extensive clinical and laboratory data collected and presented in a standardised form. Finally, our study definition may have underestimated the true prevalence of NAFLD. Despite these limitations, the study uses a very systematic approach at the population level to assess these potential associations.
In summary, our study confirms an association between HCV and DM and IR. In addition, it shows an association between HCV and hypertension. Furthermore, our study suggests that HCV patients are at increased risk for congestive heart failure. All of these findings emphasise the importance of assessing the true impact of HCV not only for its hepatic complications but also for its extra-hepatic manifestations.
  iconpaperstack View Older Articles   Back to Top   www.natap.org